E13.9

Other specified diabetes mellitus without complications

Other specified diabetes mellitus (E13) is a classification of diabetes that arises from specific etiologies distinct from type 1 and type 2 diabetes. This category includes diabetes caused by genetic defects in beta-cell function (such as Maturity-Onset Diabetes of the Young), genetic defects in insulin action, or conditions affecting the exocrine pancreas like cystic fibrosis, chronic pancreatitis, and hemochromatosis. It also encompasses diabetes induced by medications (e.g., long-term corticosteroid use) or chemicals, and diabetes associated with other endocrine disorders like acromegaly or Cushing's syndrome. The specific code E13.9 is utilized when a patient has one of these identified underlying causes for their diabetes but currently exhibits no documented microvascular or macrovascular complications, such as ketoacidosis, nephropathy, retinopathy, or neuropathy. Proper management requires monitoring of the primary etiology while maintaining glycemic targets to prevent future systemic damage.

Clinical Symptoms

  • Increased thirst (polydipsia)
  • Frequent urination (polyuria)
  • Increased hunger (polyphagia)
  • Unexplained weight loss
  • Fatigue and generalized weakness
  • Blurred vision
  • Dry mouth and skin
  • Slow-healing sores or frequent infections
  • Asymptomatic presentation (frequently identified through screening)
  • Irritability or mood changes

Common Causes

  • Diseases of the exocrine pancreas (e.g., chronic pancreatitis, cystic fibrosis, hemochromatosis, pancreatectomy)
  • Genetic defects of beta-cell function (MODY syndromes)
  • Genetic defects in insulin action
  • Endocrinopathies (e.g., Cushing's syndrome, acromegaly, pheochromocytoma, hyperthyroidism)
  • Drug- or chemical-induced (e.g., glucocorticoids, thiazides, beta-blockers, atypical antipsychotics)
  • Infections (e.g., congenital rubella, cytomegalovirus)
  • Other genetic syndromes (e.g., Down syndrome, Klinefelter syndrome, Turner syndrome, Wolfram syndrome)

Documentation & Coding Tips

Explicitly identify the underlying etiology of the diabetes mellitus to justify the use of the other specified category rather than Type 1 or Type 2.

Example: Patient with Maturity-Onset Diabetes of the Young (MODY) type 3 confirmed via genetic testing for HNF1A mutation. Current blood glucose levels are stable at 110 mg/dL without polyuria or polydipsia. No evidence of renal or retinal complications upon assessment. This genetic form of diabetes is distinct from Type 1 or Type 2 diabetes and remains stable on low-dose sulfonylureas.

Billing Focus: Identify the specific genetic defect of beta-cell function as the primary driver for the E13 code series.

Document the absence of complications clearly to support the E13.9 code and differentiate from E13 series with manifestations.

Example: Annual screening for other specified diabetes mellitus related to HNF4A mutation reveals no diabetic retinopathy on dilated eye exam and no albuminuria (uACR 12 mg/g). Neurological exam shows intact monofilament sensation bilaterally in the lower extremities. Patient remains asymptomatic and complication-free.

Billing Focus: Documentation of the absence of complications is necessary to support the .9 fifth character.

Incorporate long-term insulin use status as a secondary code (Z79.4) when applicable to the specific diabetic subtype.

Example: Patient with other specified diabetes mellitus due to genetic defects in insulin action. Condition is currently managed with a basal-bolus insulin regimen. No diabetic complications noted at this time. Current HbA1c is 6.8 percent. Patient is stable on current insulin dosing without significant hypoglycemic episodes.

Billing Focus: Requires the addition of Z79.4 to capture the complexity of pharmacological management.

Distinguish between other specified diabetes and secondary diabetes due to underlying conditions or drugs.

Example: Assessment of other specified diabetes mellitus, specifically GCK-MODY. This condition is characterized by a stable, mild fasting hyperglycemia and does not result from drug-induced factors or an underlying pancreatic disease like cystic fibrosis. No vascular complications present. Monitoring every 6 months indicated.

Billing Focus: Ensures the correct code series (E13 vs E08 or E09) is selected based on the clinical origin of the disease.

Mention the specific laboratory findings that support the diagnosis of a specified diabetes type over general Type 2.

Example: Follow-up for other specified diabetes mellitus. Low insulin requirements and absence of islet cell antibodies (GADA/IA-2) support the diagnosis of a non-Type 1, non-Type 2 genetic etiology. Glucose tolerance testing remains within stable parameters for this specified type. No manifestations of disease are present.

Billing Focus: Provides clinical evidence for the specific diagnosis, supporting the use of a more specialized ICD-10 code.

Relevant CPT Codes

Related Diagnoses

Hierarchy